Effect of Oral Vinorelbine plus Cisplatin in Unresectable Localized or Metastatic Non-Small Cell Lung Cancer (NSCLC): A Report of Stage-Ⅱ Clinical Research
LIU Dongying,WU Haiying,ZHANG Li,LIANG Ying,ZHANG Yongyu,LIU Tingzhi
DOI: https://doi.org/10.3969/j.issn.1000-8179.2010.14.012
2010-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective: To evaluate the efficacy of oral vinorelbine plus cisplatin and Ⅳ vinorelbine plus cisplatin in advanced non-small-cell lung cancer (NSCLC), and to appraise the progression-free survival, toxicity, and the safety of both therapeutic applications. Methods: Patients who met the inclusion criteria were randomly (1:1) assigned to the experimental group with oral vinorelbine plus cisplatin (arm A) or the control group with intravenous (Ⅳ) vinorelbine plus cisplatin (arm B). Patients in both the groups were treated with the two therapeutic regimens administered once every 3 weeks. In the first course of treatment, the oral vinorelbine was administrated at a dose of 60 mg/m~2 on day 1 and 8, while the IV vinorelbine was administrated at a dose of 25 mg/m~2 on day 1 and 8. In both groups, cisplatin was administrated at the dose of 80 mg/m~2 on day 1. In the second course of treatment, the dose of oral vinorelbine was raised up to 80 mg/m2 and the Ⅳ vinorelbine was raised to 30 mg/m~2 for the following cycles, if no severe hematological toxicity was found in these patients. Tumor response rate was appraised according to RECIST criteria, and the toxicity grading was appraised based on NCI-CTC Version 2.0. Results: A total of 39 eligible subjects were enrolled in the Cancer Center of Sun Yat-Sen University, with 19 in the experimental group and 20 controls. Characteristics including gender, age, performance status, clinical stage, histo-types and smoking status were balanced in the patients of both groups. Data were analyzed in the intention-to-treat manner. The objective remission rate was 31.6% and 42.1% (P=0.737), and the clinical benefit rate was 52.6% and 68.4% (P=0.508) in arm A and B, respectively. The median progression-free survival was 85 and 115 days, respectively, in arm A and B (P=0.705). Toxic reactions in both groups included neutropenia, anemia, gastrointestinal reactions and phlebitis. Grade-2 phlebitis notably increased in arm B (68.4% vs. 21.0%), with a statistically significant difference between the two groups (P=0.008). No significant differences were found in the comparison of other adverse effects and grade- Ⅲ～Ⅳ un- toward reactions between the subjects of the 2 groups. Conclusion: The efficacy of oral vinorelbine plus cisplatin regimen is similar to that of the Ⅳ vinorelbine and cisplatin regimen in the cases with advanced non-small-cell lung cancer (NSCLC). The hematological toxicity and non-hematological toxicity were lower in the experimental group than in the controls. A larger -scale phase-Ⅲ clinical study is needed to further evaluate the efficacy and toxicity of oral vinorelbine in Asian patients.